Baillie Gifford & Co Portfolio holdings
Baillie Gifford & Co., founded in 1908 by Lt Col Augustus Baillie and Carlyle Gifford and headquartered in Edinburgh, Scotland, is an independent, partnership-owned investment management firm renowned for its long-term, growth-oriented approach, managing over £230 billion ($290 billion USD) in assets as of late 2024. Focusing primarily on global equities, the firm serves institutional clients like pension funds and retail investors through mutual funds and investment trusts, such as the Scottish Mortgage Investment Trust, emphasizing fundamental research into innovative, high-growth companies—often holding stakes in firms like Tesla and Amazon for decades. With around 2,000 employees across offices in London, New York, Hong Kong, and beyond, Baillie Gifford operates without external ownership pressures, allowing its 58 partners to prioritize patience and conviction over short-term market trends. Known for its low-profile culture and ESG integration, the firm has earned a reputation as a thoughtful, contrarian investor in a world of rapid-fire trading.
Top Buys
| 1 |
Joby Aviation
JOBY
|
$453M |
| 2 |
Datadog
DDOG
|
$423M |
| 3 |
Cloudflare
NET
|
$378M |
| 4 |
Mercado Libre
MELI
|
$311M |
| 5 |
Amazon
AMZN
|
$290M |
Top Sells
| 1 |
Tesla
TSLA
|
$750M |
| 2 |
Booking.com
BKNG
|
$484M |
| 3 |
Netflix
NFLX
|
$450M |
| 4 |
Spotify
SPOT
|
$372M |
| 5 |
Carvana
CVNA
|
$364M |
Sector Composition
| 1 | Consumer Discretionary | 27.35% |
| 2 | Technology | 24.66% |
| 3 | Healthcare | 18.87% |
| 4 | Communication Services | 12.6% |
| 5 | Financials | 5.85% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
376
Exelixis
EXEL
$10.1B
| – | – | -1,395 | Closed | -$27.1K |
|
377
Expeditors International
EXPD
$16.4B
| – | – | -125 | Closed | -$13.8K |
|
378
Expedia Group
EXPE
$26.6B
| – | – | -199 | Closed | -$19.3K |
|
379
Exponent
EXPO
$3.6B
| – | – | -265 | Closed | -$26.4K |
|
380
Fate Therapeutics
FATE
$120M
| – | – | -372 | Closed | -$2.12K |
|
381
Factset
FDS
$14.1B
| – | – | -80 | Closed | -$33.2K |
|
382
FibroGen
FGEN
$47.8M
| – | – | -539 | Closed | -$10.1K |
|
383
Amicus Therapeutics
FOLD
$2.34B
| – | – | -538 | Closed | -$5.97K |
|
384
Fox Class A
FOXA
$26.6B
| – | – | -480 | Closed | -$16.3K |
|
385
Fastly
FSLY
$1.12B
| – | – | -205 | Closed | -$3.64K |
|
|
GAN
386
DELISTED
GAN Ltd
GAN
| – | – | -572 | Closed | -$738 |
|
387
Graco
GGG
$14.1B
| – | – | -401 | Closed | -$29.3K |
|
388
Corning
GLW
$57.4B
| – | – | -731 | Closed | -$25.8K |
|
389
Gentex
GNTX
$6.15B
| – | – | -583 | Closed | -$16.3K |
|
390
Goodyear
GT
$2.43B
| – | – | -1,706 | Closed | -$18.8K |
|
391
W.W. Grainger
GWW
$48.5B
| – | – | -68 | Closed | -$46.8K |
|
392
Healthcare Services Group
HCSG
$1.13B
| – | – | -157 | Closed | -$2.18K |
|
393
Hillenbrand
HI
$1.79B
| – | – | -170 | Closed | -$8.08K |
|
394
Heron Therapeutics
HRTX
$207M
| – | – | -308 | Closed | -$465 |
|
395
Humana
HUM
$36.5B
| – | – | -64 | Closed | -$31.1K |
|
|
BRSL
396
Brightstar Lottery PLC
BRSL
$3.15B
| – | – | -1,271 | Closed | -$34.1K |
|
397
Incyte
INCY
$16.5B
| – | – | -165 | Closed | -$11.9K |
|
398
InMode
INMD
$944M
| – | – | -659 | Closed | -$21.1K |
|
399
Insmed
INSM
$28.8B
| – | – | -802 | Closed | -$13.7K |
|
400
Jazz Pharmaceuticals
JAZZ
$7.75B
| – | – | -193 | Closed | -$28.2K |
|